Carina Biotech

An Australian clinical stage immunotherapy company established to research and develop chimeric antigen receptor T cell (CAR-T) therapies to treat solid cancers. Carina are working towards producing broad-spectrum CAR-T therapies that can be used to treat multiple solid cancers yet are patient-specific and result in little, if any, off-cancer damage. Using its proprietary platforms, Carina is also developing technologies to improve access to, and infiltration of, solid cancers, and to enhance CAR-T cell manufacturing.
We are working to…

1. Expand the clinical indications for T cell therapies 

2. Improve the commercial viability of T cell therapies by developing supporting technologies that make T cell therapies more effective or economically viable

Headquartered in Adelaide, South Australia, Carina has strong T cell R&D capability across a network of research providers and collaborators including leading scientists at the UniSA, the Women's & Children's Hospital in Adelaide, the University of Adelaide, the Royal Prince Alfred Hospital in NSW and the Seattle Children's Hospital in the United States.

Biotechnology

Health Care

Life Sciences

Research

Therapeutics

Carina Biotech

Deborah Rathjen

Leanna Read

Stephen Livesey

Remus Vezan

Yulii Bogatyrenko

Rohina Batra

Jose Iglesias

The Research and Development team at Carina Biotech focuses on advancing chimeric antigen receptor T cell (CAR-T) therapies for solid cancers. They drive innovation in expanding clinical applications, improving the effectiveness and economic viability of these therapies, and developing supporting technologies. By collaborating with leading research institutions, the team aims to enhance CAR-T cell manufacturing and improve patient-specific treatment outcomes while minimizing off-cancer damage.

Research and Development

Leadership Team

Research and Development

About

Team members

Other teams at Carina Biotech

Leadership Team